Research papers: - Clinical Papers: 5
- The Effects of Liv.52 DS Tablets on Various Liver Parameters in Non-Alcoholic Fatty Liver Disease: Preliminary Trend Identified from a Cumulative Efficacy Analysis.
Sharad C. Shah, Department of Gastroenterology, J.J. Group of Hospitals, Mumbai, India, Prasanna S. Shah, Department of Gastroenterology, Breach Candy, Jaslok & Saifee Hospitals, Mumbai, India, Nusly P. J. Pocha, Medical Consultant to Air France, KLM and Lufthansa German Airlines, India, Gontar Siregar, Department of Internal Medicine, University of Sumatera Utara, Medan, Indonesia. Srikrishna H A, R&D, Himalaya Wellness Company (HWC), Bengaluru, India, Rajesh Kumawat, Head- Medical Services and Clinical Development, R&D, Himalaya Wellness Company (HWC), Bengaluru, India. International Journal of Pharmaceutical and Clinical Research 2022; 14(6); 739-751.
- A prospective, interventional clinical study to evaluate the safety and efficacy of Liv.52 DS in the management of non-alcoholic fatty liver disease.
Gontar Siregar, Division of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Sumatera Utara, Medan, Indonesia, Rangesh Paramesh, Rajesh Kumawat, Palaniyamma D, Srikrishna HA, The Himalaya Drug Company, Makali, Bengaluru, India. European Journal of Clinical and Experimental Medicine 2021; 19 (2): 129–136.
Non alcoholic Fatty Liver Disease (NAFLD)
- Clinical and Safety Evaluation of Liv.52 in Alcoholic Liver Disease: A Review
Subramanian Ganesh, GE Clinic & Endoscopy Centre & MIOT Hospital, Chennai, India Neeraj Joshi, Nepal Mediciti Hospital and Nepal Cancer Hospital & Research Centre, Lalitpur, Nepal, Mukesh Kumar Jain, MG Medical College & Hospital, Jaipur, India, Lokendra Sharma, Department of Pharmacology, SMS Medical College, Jaipur, India, Anish Desai, Intellimed Healthcare Solutions, Mumbai, India, Mohamed Rafiq, Uddagiri Venkanna Babu and Rajesh Kumawat, Research and Development, Himalaya Wellness Company, Bengaluru, India. Gastroenterology Insights 2022, 13, 377–386.
- Liv.52 DS Syrup in the Management of Alcoholic Hepatitis: An Open Label Study
S Ganesh, Consultant Gastroenterologist and Hepatologist, Chennai, D Palaniyamma and Suprabha Hegde, Medical Advisor, Research Associate R&D Center, The Himalaya Drug Company, Makali, Bangalore. Indian Journal of Clinical Practice, Vol. 21, No. 12, May 2011: 645-649.
Alcoholic Liver Disease (ALD)
- Role of Liv.52 DS Tablets as a Hepatoprotective Agent in Tuberculosis Patients Receiving Antitubercular Drugs: A Double Blind Placebo Controlled Study.
Gotoviin Choijamts, Ch.Batsyren, Orkhon B, Otgontyr, Otoch Manramba Medical Institute, Ulaan Baatar, Mongolia, Narantstsetseg D, Oyunerdene X, Zagirjav T, Songino khairkhan district hospital, Mongolia, Erdenesuvd, Enkhbayar, Pyrevbazar Bayangol district hospital, Mongolia, Oyundelger, Tungalag, Nalaikh district hospital, Mongolia, Erdenetsetseg D, Enkhtsetseg, Baga nuur district hospital, Mongolia, Bilegmaa M, Dornogovi provincial hospital, Mongolia, Sarantuya S, Bayanzyrkh district hospital, Mongolia and Palaniyamma D, Department of Clinical trial and Medical Services, The Himalaya Drug Company, India. Journal of Liver and Clinical Research 5(1): 1042 (2018).
Drug Induced Liver Injury (DILI)